Table 2.

In vitro antiviral activity of azithromycin.

Targeted virus	Antiviral activity screening system	Time of drug addition to infected cell culture	Incubation period	MOI	IC50 or EC50 (μM)	CC50 (μM)	SIa	Reference
SARS-CoV-2	Vero cells	15 min pre-treatment	72 h	0.002	2.12 EC90: 8.65	>40	>19	62
Zika	Vero cells	12 h pre-treatment	48 h	0.1	6.59	810	123	63
Ebola	Vero 76 cells	1 h pre-treatment	48 h	0.2	5.1	>130	>25	64
Influenza	A549 cells	Simultaneous	48 h	1	68	>600	>8.8	59
Dengue	Vero cells	12 h pre-treatment	48 h	0.01	3.71	810	218	63

CC₅₀, 50% cytotoxic concentration; EC₅₀, 50% effective concentration; H1N1, influenza A virus subtype H1N1; IC₅₀, 50% inhibitory concentration; MOI, multiplicity of infection; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SI, selectivity index (CC₅₀/IC₅₀).

^aReported or calculated.